RINL gene and anti-aging application of antagonist thereof

Through the RINL gene and its antagonists, the problem of lack of effective anti-aging drugs in the prior art has been solved, the effect of extending life and improving aging situation has been achieved, and new anti-aging treatment ideas have been provided.

CN119055771APending Publication Date: 2024-12-03XIAMEN UNIV
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411040085.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The lack of effective anti-aging drugs in the existing technology has led to the intensification of global aging problems and brought huge challenges to the medical system and economic development.

Method used

RINL gene and its antagonists are used to diagnose and detect aging status, prepare drugs that delay aging, and screen drugs that prevent and relieve aging by detecting changes in RINL gene expression, including using siRNA to knock down RINL expression to improve cells and mice aging situation.

Benefits of technology

RINL-KO significantly extends the lifespan of mice, improves the motility and metabolic capacity of aging mice, and reduces the expression of β-galactosidase, aging marker in cells and in the liver of mice, providing new ideas and targets for anti-aging. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004972158260000041
    Figure BDA0004972158260000041
  • Figure BDA0004972158260000061
    Figure BDA0004972158260000061
  • Figure BDA0004972158260000101
    Figure BDA0004972158260000101
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to an anti-aging application of an RINL gene and an antagonist thereof. Specifically, the invention provides an application of an RINL gene or an encoding protein thereof, and the RINL gene or the encoding protein thereof: (1) is used as a marker for diagnosis, detection or prognosis of aging; or (2) preparing a reagent or a kit for diagnosing or detecting an aging state; or (3) preparing a medicine for delaying senescence. Experimental results show that the RINL-KO can improve the aging condition of cells and improve the movement and metabolic capability of old mice. Therefore, the invention proposes that the RINL is used as a new anti-aging target for the first time, has important significance for screening new drugs, and also provides a new thought for anti-aging treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to an anti-aging use of a RINL gene and an antagonist thereof. Background Art

[0002] Aging is an inevitable process of life as time goes by, which is mainly manifested in the decline of adaptability and resistance, impairment of physiological functions, degenerative changes in tissues and organs, and ultimately the inevitable process of death. With the aging of the body, the incidence of many chronic diseases such as heart disease, cancer, diabetes, Alzheimer's disease, etc. has increased sharply. In recent years, with the increase in the average life expectancy of human beings and the decline in birth rate, the age structure of the global population has been changing, mainly manifested in the continuous decrease in the number of people aged 0-15, accompanied by the continuous increase in the number of people over 65. Nowadays, the number of elderly people over 65 is significantly higher than the number of people under 5 years old, and this trend will continue, which means that the degree of global aging is aggravated. This population change will have a significant impact on the operation of the national medical system and impose a heavy burden on economic development. Therefore, delaying aging, preventing, delaying, alleviating and even reversing the process of age-related diseases has become the key to solving the aging problem in countries around the world, and finding anti-aging drugs is urgent.

[0003] However, there is currently a lack of satisfactory anti-aging drugs. Therefore, there is an urgent need in the art to develop new safe and effective anti-aging methods and pharmaceutical compositions. Summary of the invention

[0004] In order to solve the problems existing in the prior art, the purpose of the present disclosure is to provide anti-aging uses of RINL gene and its antagonist.

[0005] In order to achieve the above objectives, the present disclosure adopts the following specific scheme:

[0006] In one aspect, the present disclosure provides uses of the RINL gene or its encoded protein, wherein the RINL gene or its encoded protein: (1) is used as a marker for diagnosing, detecting or prognosing aging; or (2) is used to prepare a reagent or kit for diagnosing or detecting the aging state; or (3) is used to prepare a drug for delaying aging.

[0007] In another aspect, the present disclosure provides use of a RINL antagonist in preparing a drug for preventing and / or alleviating aging, wherein the drug is used for.

[0008] On the other hand, the present disclosure provides a method for screening drugs for preventing and / or alleviating aging, which comprises the following steps: detecting changes in the expression level of RINL gene in the body before and after administration.

[0009] In another aspect, the present disclosure provides a pharmaceutical composition for preventing and / or alleviating aging, comprising a RINL antagonist that inhibits RINL expression, and optionally a pharmaceutically acceptable carrier or excipient.

[0010] The beneficial effects of the present disclosure are at least as follows:

[0011] The applicant unexpectedly discovered that the expression of the RINL gene may be related to the degree of individual aging. Experiments have shown that RINL-KO can improve the aging of cells and mice, extend the lifespan of mice, and improve the movement and metabolic capacity of aged mice. Specifically, RINL-KO also reduced the expression of β-galactosidase, a marker of aging, in cells and in the liver of mice. Therefore, the present invention discloses for the first time that RINL can be used as a new target for anti-aging, which is of great significance for screening new drugs and provides a new idea for anti-aging treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 Shown is the effect of knocking down RINL expression in HK2 cells using siRNA on cell viability and β-gal expression.

[0013] Figure 2 Shown is the lifespan-extending effect of RINL-KO in male as well as female mice.

[0014] Figure 3 The results show the effect of RINL-KO on the metabolic status of male and female aged mice (24 months old).

[0015] Figure 4 Shown are the effects of RINL-KO on the motor performance of male and female aged mice (24 months old).

[0016] Figure 5 The results show that RINL-KO alleviates the effect of Klotho expression level in D-gal-induced accelerated aging model mice.

[0017] Figure 6 The results show the effect of RINL-KO on the metabolic status of male and female senescence-accelerated mice.

[0018] Figure 7 The results show that RINL-KO alleviates the effects on exercise capacity in male and female senescence-accelerated mice.

[0019] Figure 8 The results show that RINL-KO alleviates the effect of D-gal-induced rapid aging model mice on the body weight ratio of various important organs.

[0020] Fig. 9 The results show that RINL-KO alleviates the degree of liver aging in D-gal-induced rapid aging model mice. DETAILED DESCRIPTION

[0021] I. Terminology

[0022] In order to make the present disclosure more easily understood, certain technical and scientific terms are specifically defined below. Unless otherwise clearly defined elsewhere in this document, all other technical and scientific terms used herein have the meaning commonly understood by those skilled in the art to which the present disclosure belongs.

[0023] As used herein, the articles "a" and "an" refer to one or more than one (ie, at least one) of the grammatical object to which the article refers. For example, "an element" means one element or more than one element.

[0024] As used herein, the term "RINL" stands for Ras And Rab Interactor Like, which is involved in a variety of biological processes in cells, especially related to vesicle-mediated transport and the regulation of Rab proteins. The protein expressed by RINL can activate the Rab5 subfamily small GTPase, thereby playing a role in endocytosis. RINL is expressed in a variety of tissues, especially in the thymus and spleen, where the expression level is high.

[0025] As used herein, the term "Klotho" gene is located on human chromosome 13 (13q12), has a total length of 50kb, and consists of 5 exons. Through alternative splicing, Klotho can produce two proteins, one is a membrane protein (mainly expressed in the kidney, placenta, small intestine and prostate), and the other is a circulating protein (mainly expressed in tissues such as the brain, hippocampus, placenta, kidney, prostate and small intestine). The membrane protein form can also produce a circulating form of protein by hydrolysis. Klotho has been shown to have anti-aging effects, and the level of Klotho in serum can also reflect the degree of aging in mice. The higher the level of Klotho, the lower the degree of aging in mice. There are two forms of Klotho protein: αKlotho and βKlotho, which are the main parts of the endocrine fibroblast growth factor (FGF) receptor complex and are required for high affinity binding of FGF19, FGF21 and FGF23 to their corresponding FGF receptors.

[0026] As used herein, the expressions "cell," "cell line," and "cell culture" are used interchangeably, and all such names include progeny thereof. Thus, the words "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom, without regard to the number of transfers. It should also be understood that all progeny may not be exactly identical in terms of DNA content, due to intentional or unintentional mutations. Mutant progeny having the same function or biological activity as screened for in the originally transformed cell are included. Where different names are intended, this is clear from the context.

[0027] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and where it does not occur.

[0028] "Administering," "giving," and "treating" when applied to animals, humans, experimental subjects, cells, tissues, organs, or biological fluids, refers to the contact of an exogenous drug, therapeutic agent, diagnostic agent, or composition with an animal, human, subject, cell, tissue, organ, or biological fluid. "Administering," "giving," and "treating" can refer to, for example, treatment, pharmacokinetics, diagnosis, research, and experimental procedures. Treatment of cells includes contact of an agent with a cell, and contact of an agent with a fluid, wherein the fluid is in contact with the cell. "Administering," "giving," and "treating" also mean in vitro and ex vivo treatment of, for example, a cell, by an agent, a diagnosis, a combination composition, or by another cell. "Treatment," when applied to humans, veterinary medicine, or research subjects, refers to therapeutic treatment, prophylactic or preventative measures, research and diagnostic applications.

[0029] "Treatment" means administering an internal or external therapeutic agent to a patient who has one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect. Generally, the therapeutic agent is administered in an amount effective to alleviate one or more symptoms of a disease in the patient or population being treated, either by inducing regression of such symptoms or inhibiting the progression of such symptoms to any clinically unmeasurable degree. The amount of a therapeutic agent effective to alleviate any specific disease symptom (also referred to as a "therapeutically effective amount") may vary according to a variety of factors, such as the disease state, age, and weight of the patient, and the ability of the drug to produce the desired therapeutic effect in the patient. Whether a disease symptom has been alleviated may be assessed by any clinical test method commonly used by a physician or other health care professional to assess the severity or progression of the symptom. Although the embodiments of the present disclosure (e.g., treatment methods or articles) may not be effective in alleviating the target disease symptoms that every patient has, they should alleviate the target disease symptoms in a statistically significant number of patients as determined by any statistical test known in the art, such as Student's t test, chi-square test, U test according to Mann and Whitney, Kruskal-Wallis test (H test), Jonckheere-Terpstra test, and Wilcoxon test. The term "treating" an individual suffering from a disease or disease condition means that the symptoms of the individual are partially or completely alleviated, or remain unchanged after treatment. Therefore, treatment includes prevention, treatment, and / or cure. Prevention refers to preventing underlying diseases and / or preventing symptom deterioration or disease development. Treatment also includes any pharmaceutical use of any chimeric antigen receptor provided and the compositions provided herein.

[0030] As used herein, the terms "effective amount" or "therapeutically effective amount" are used interchangeably herein and refer to an amount of a compound, formulation, substance or composition as described herein that is effective to achieve a particular biological result or provide a therapeutic or prophylactic benefit.

[0031] The term "consisting essentially of" or variations thereof as used throughout the specification and claims means including all recited elements or groups of elements, and optionally including other elements of similar or different properties to the recited elements, which other elements do not significantly alter the basic or novel properties of a specified dosing regimen, method, or composition.

[0032] The term "antagonist" refers to a substance that can act at the nucleic acid or protein level to reduce or inhibit the expression or activity of RINL. It includes but is not limited to shRNA, siRNA, miRNA, dsRNA, small molecule compounds, stRNA, aptamers, or antibodies or their antigen-binding fragments.

[0033] A "vector" is a composition of matter that contains an isolated nucleic acid and can be used to deliver the isolated nucleic acid into a cell. Many vectors are known in the art, including but not limited to linear polynucleotides, polynucleotides associated with ions or amphipathic compounds, plasmids and viruses. Therefore, the term "vector" includes an autonomously replicating plasmid or virus. The term should also be interpreted to include non-plasmid and non-viral compounds that promote the transfer of nucleic acids into cells, such as, for example, polylysine compounds, liposomes, etc. Examples of viral vectors include but are not limited to adenoviral vectors, adeno-associated viral vectors, retroviral vectors, etc.

[0034] The terms "patient," "subject," "individual," and the like are used interchangeably herein and are intended to include living organisms (e.g., mammals) in which an immune response can be elicited. Examples of subjects include humans, dogs, cats, mice, rats, and transgenic species thereof.

[0035] The term "kit" is any product (e.g., a package or container) containing at least one reagent (e.g., a therapeutic agent, a probe, a small molecule, etc.) for specific detection and / or therapeutically affecting the expression of the markers described in the present invention. The kit can be promoted, distributed or sold as a whole for performing the method described in the present invention. The kit may contain one or more reagents, which are necessary for the expression of the composition used in the method described in the present invention. In certain embodiments, the kit may further contain a reference standard, for example, a nucleic acid encoding a protein that does not affect or regulate a signaling pathway that controls an immune response, cell growth, division, migration, survival or apoptosis. A person skilled in the art can envision many such control proteins, including but not limited to: common molecular tags (e.g., green fluorescent protein and β-galactosidase); proteins that are not included in the classification of any pathway including cell growth, division, migration, survival or apoptosis by GeneOntology reference; or ubiquitous housekeeping proteins. The reagents in the kit may be provided by a single container, or by a mixture of two or more reagents in a single container. In addition, explanatory materials describing the use of the composition in the kit may be included.

[0036] Abbreviations

[0037]

[0038] II. Detailed description of specific implementation scheme

[0039] In one aspect, the present disclosure provides uses of the RINL gene or its encoded protein, wherein the RINL gene or its encoded protein: (1) is used as a marker for diagnosing, detecting or prognosing aging; or (2) is used to prepare a reagent or kit for diagnosing or detecting the aging state; or (3) is used to prepare a drug for delaying aging.

[0040] In another aspect, the present disclosure provides use of a RINL antagonist in preparing a drug for preventing and / or alleviating aging.

[0041] In some embodiments, the medicament can also improve the subject's motor and metabolic capacity.

[0042] In some embodiments, the RINL antagonist specifically targets the nucleotide sequence shown in SEQ ID NO.1 or specifically binds to the amino acid sequence shown in SEQ ID NO.2, and has any of the following functions:

[0043] (1) Inhibit RINL gene expression;

[0044] (2) Deletion or silencing of the RINL gene;

[0045] (3) knockout of the RINL gene;

[0046] (4) Antagonize RINL protein.

[0047] In some embodiments, the RINL antagonist is selected from shRNA, siRNA, miRNA, dsRNA, stRNA, a small molecule compound, an aptamer, an antibody, or an antigen-binding fragment thereof.

[0048] In some embodiments, the antibody or antigen-binding fragment thereof is selected from a whole antibody, a F(ab)-fragment, a F(ab)2-fragment, a single-chain antibody, a chimeric antibody, a bivalent antibody-construct, a synthetic antibody, a bispecific single-chain antibody or a cross-cloned antibody.

[0049] In some embodiments, the RINL antagonist is an anti-RINL antibody.

[0050] In some embodiments, the RINL antagonist is a siRNA comprising a sense strand and an antisense strand, which are 15-30 base pairs in length, and the antisense strand comprises a complementary region complementary to an mRNA encoding RINL.

[0051] In some embodiments, the nucleotide sequence of the siRNA is selected from any one of the following combinations of sense strands and antisense strands:

[0052] (1) a sense strand having a sequence as shown in SEQ ID NO.3, and an antisense strand having a sequence as shown in SEQ ID NO.4; or

[0053] (2) a sense strand having a sequence as shown in SEQ ID NO.5, and an antisense strand having a sequence as shown in SEQ ID NO.6; or

[0054] (3) A sense strand having the sequence shown in SEQ ID NO.7, and an antisense strand having the sequence shown in SEQ ID NO.8.

[0055] In some embodiments, the medicament is capable of reducing the expression of β-galactosidase in cells and individuals.

[0056] In some embodiments, the drug is capable of increasing the expression of Klotho in cells and individuals.

[0057] In some embodiments, the medicament includes an active ingredient, a RINL antagonist, and a pharmaceutically acceptable carrier or excipient.

[0058] In some embodiments, the content of the RINL antagonist in the drug is 1% to 99%.

[0059] On the other hand, the present disclosure provides a method for screening drugs for preventing and / or alleviating aging, comprising the following steps: detecting changes in the expression of RINL gene in the body before and after administration. In some embodiments, the method uses the expression level of RINL gene as a screening indicator.

[0060] In another aspect, the present disclosure provides a pharmaceutical composition for preventing and / or alleviating aging, comprising a RINL antagonist that inhibits RINL expression, and optionally a pharmaceutically acceptable carrier or excipient.

[0061] In some embodiments, the pharmaceutical composition further comprises one or more additional therapeutic components.

[0062] On the other hand, the present disclosure provides a RINL antagonist, wherein the RINL antagonist specifically targets the nucleotide sequence shown in SEQ ID NO.1 or specifically binds to the amino acid sequence shown in SEQ ID NO.2, and has any of the following functions:

[0063] (1) Inhibit RINL gene expression;

[0064] (2) Deletion or silencing of the RINL gene;

[0065] (3) knockout of the RINL gene;

[0066] (4) Antagonize RINL protein.

[0067] In some embodiments, the RINL antagonist is a siRNA comprising a sense strand and an antisense strand, which are 15-30 base pairs in length, and the antisense strand comprises a complementary region complementary to an mRNA encoding RINL.

[0068] In some embodiments, the nucleotide sequence of the siRNA is selected from any one of the following combinations of sense strands and antisense strands:

[0069] (1) a sense strand having a sequence as shown in SEQ ID NO.3, and an antisense strand having a sequence as shown in SEQ ID NO.4; or

[0070] (2) a sense strand having a sequence as shown in SEQ ID NO.5, and an antisense strand having a sequence as shown in SEQ ID NO.6; or

[0071] (3) A sense strand having the sequence shown in SEQ ID NO.7, and an antisense strand having the sequence shown in SEQ ID NO.8.

[0072] In another aspect, the present disclosure provides nucleic acids encoding the aforementioned RINL antagonists.

[0073] In another aspect, the present disclosure provides an expression vector comprising the aforementioned nucleic acid.

[0074] In another aspect, the present disclosure provides a cell comprising the aforementioned nucleic acid and an expression vector.

[0075] In another aspect, the present disclosure provides a composition comprising the aforementioned RINL antagonist, and optionally a pharmaceutically acceptable carrier or excipient.

[0076] In another aspect, the present disclosure provides a use of the aforementioned use, the aforementioned RINL antagonist and / or the aforementioned composition in the preparation of a medicament for treating and / or preventing aging of an individual, wherein the medicament is administered to the individual in an effective amount.

[0077] In another aspect, the present disclosure provides a method for treating anti-aging by administering a therapeutically effective amount of the aforementioned RINL antagonist and / or the aforementioned composition to a subject.

[0078] Example

[0079] A further understanding of the present disclosure may be obtained by reference to some specific embodiments given herein, which are only used to illustrate the present disclosure and are not intended to limit the scope of the present disclosure in any way. Obviously, various modifications and variations may be made to the present disclosure without departing from the essence of the present disclosure, and therefore, these modifications and variations are also within the scope of the present application. The clinical trial data used in the present disclosure have been obtained with the knowledge and consent of the subjects.

[0080] Example 1: Knocking down the expression of RINL in HK2 cells using siRNA can alleviate cell senescence

[0081] The applicant unexpectedly discovered that the expression level of the RINL gene may be related to the degree of individual aging. HK2 cells, human renal proximal tubule cells, are a common model cell used in kidney disease-related research. Considering that kidney disease is highly correlated with the degree of individual aging, siRNA was used to knock down RINL expression in HK2 cells to study the relationship between RINL and aging. Three groups of siRNA targeting RINL were designed, and their sequence information is shown in Table 1 below. RINL was knocked down using siRNA by liposome transfection. HK2 cells were lysed to collect proteins, and the intracellular RINL expression level was analyzed by immunoprotein blotting. The results are shown in 1A, and siRNA significantly reduced the expression of RINL in HK2 cells.

[0082] In addition, after knocking down RINL in HK2 cells by siRINL liposome transfection, the cells were subjected to rapid senescence modeling (cells were treated with 200 μmol / L hydrogen peroxide for 24 h), and then cell viability was detected by thiazolyl blue staining (Methylthiazolyldiphenyl-tetrazolium bromide, MTT) (Beijing Coolbo Technology Co., Ltd.; CM7461), and the cells were stained with β-galactosidase (β-gal, a cell senescence marker) (Biyuntian; C0602) to observe the expression of intracellular β-gal. Figure 1 B-1C shows that hydrogen peroxide treatment causes a significant decrease in cell viability and increases the expression of β-gal, a marker of cell senescence, in cells. Knocking down RINL expression can alleviate the decrease in cell viability caused by hydrogen peroxide treatment and alleviate the abnormal increase in β-gal, a marker of cell senescence, and tends to restore cells to normal levels. That is, the reduction in RINL expression can enable HK2 cells to resist the rapid cell senescence caused by hydrogen peroxide.

[0083] Table 1 Sequence information of siRINL

[0084]

[0085] Example 2: RINL-KO extends the lifespan of mice

[0086] In order to study whether RINL knockout can extend the lifespan of mice, we knocked out the RINL gene in female and male mice (knocked out at birth) and set up a blank control. Each group of mice was fed naturally to ensure their normal diet. All feeding conditions were kept consistent and continuous observation was carried out. Whether there were new deaths of mice every day (to ensure the accuracy of the death date statistics) was observed. There were two groups of male and female mice, RINL systemic knockout mice and control mice, with ten mice in each group, to observe the effect of RINL gene on the lifespan of mice. The statistical results of the survival curve are shown in Figure 2 It was found that RINL gene knockout has the effect of extending the lifespan of mice in both female and male mice.

[0087] Example 3: RINL-KO improves metabolic capacity and exercise capacity in aged mice

[0088] The metabolic state and exercise capacity of old mice are important indicators for assessing their degree of aging. The more vigorous the metabolic activity and the stronger the exercise capacity, it usually means that the old mice have better health and may indicate that they have a longer life expectancy. Therefore, testing the exercise capacity and metabolic capacity of old mice has become a routine method in aging-related research.

[0089] In order to study whether RINL knockout can improve the aging of mice, 24-month-old mice (including female and male) were selected in this example, and a blank control group (WT) and a RINL gene knockout group (RINL-KO) were set up. The metabolism of the mice was monitored using a 16-channel metabolic monitoring system (Promethion Core), and the metabolic values ​​of the mice within 24 hours were counted. The results are shown in Figure 3 Regardless of day or night, the 24-hour energy expenditure (EE) of female and male RINL-KO mice was significantly higher than that of the control group. This indicates that knocking out the RINL gene enhanced the basal metabolism of mice and improved the oxygen consumption level of mice, which is beneficial to improving the health of aged mice.

[0090] Movement and coordination ability are also important indicators for evaluating aging. In this example, the grasping strength (Ugo47200) and running ability (Ugo Basile 47300) of the aged mice in the above groups were further detected. Figure 4 The results of A and 4B showed that RINL-KO significantly improved the motor ability of aged mice, which further confirmed the positive effect of RINL-KO on improving the health of aged mice.

[0091] Example 4: Construction of Rapid Aging RINL-KO and WT Mouse Models

[0092] Because it is impossible to take organ and serum samples after the death of naturally aged mice, and it is impossible to detect more molecular indicators, we constructed a rapid aging mouse and induced it with D-galactose (D-gal) (Merck; G0750). D-gal can increase the production of reactive oxygen species (ROS), leading to oxidative stress. Long-term oxidative stress can damage cell membranes, proteins and DNA, and accelerate cell aging. RINL systemic knockout and wild-type C57BL / 6 mice were selected, both male and female were eight weeks old, 8 mice in each group, and D-gal 120-200 mg / kg / day was injected intraperitoneally for 12 weeks (120 mg / kg for females and 200 mg / kg for males) to induce a rapid aging model. The groups were: WT+NaCl treatment group, WT+D-gal treatment group, RINL-KO+NaCl treatment group, and RINL-KO+D-gal treatment group.

[0093] In order to verify whether the model was successfully established and the effect of RINL knockout, blood was collected from the mice under the jaw, and serum was obtained by centrifugation. The Klotho expression level was detected using a kit (D721177-0048). The Klotho level in serum can also reflect the degree of aging of mice.

[0094] Test results see Figure 5 The Klotho level in the serum of the rapid aging model mice decreased significantly in both female and male mice, and the downward trend of Klotho in the serum of RINL-KO aged mice was significantly alleviated, and the expression level of Klotho in their serum tended to normal levels.

[0095] Example 5: RINL-KO improves metabolism and exercise capacity in a senescence-accelerated mouse model

[0096] Testing the physical fitness and metabolic capacity of elderly mice has become an indispensable standard practice for studying aging. In order to further explore the potential improvement effect of RINL gene knockout on the rapid aging process of mice, we tested four groups of mice in the rapid aging model, including: WT+Nacl treatment group, WT+D-gal treatment group, RINL-KO+Nacl treatment group, RINL-KO+D-gal treatment group. The metabolic activity of mice was tracked using a 16-channel metabolic monitoring device (Promethion Core), and their metabolic data were recorded within 24 hours. The relevant results are shown in Figure 6Whether during the day or at night, the 24-hour energy expenditure (EE) of female and male mice in the RINL-KO group was significantly higher than that of the control group. This indicates that after knocking out the RINL gene, the basal metabolic rate of mice was increased, the oxygen consumption level was optimized, and it was beneficial to improve the health level of rapidly aging mice.

[0097] The rapidly aging mice in the above groups were further tested for their grip strength (Ugo47200) and running ability (UgoBasile47300). Figure 7 The test results of A and 7B showed that RINL-KO significantly enhanced the motor performance of rapidly aging mice, which further verified the positive effect of RINL gene knockout on improving the health level of rapidly aging mice. In addition, RINL-KO had little effect on normal mice (comparison within the NaCl treatment group). The above results show that knocking out RINL has an anti-aging effect and does not affect other physiological functions of mice under normal conditions.

[0098] Example 6: RINL-KO improves liver aging in senescent-accelerated mice

[0099] After the in vivo experiment, the mice in the above groups were killed and samples were collected to collect various organs, detect molecular indicators and explore possible molecular mechanisms. Specifically, the female and male mice in the WT+NaCl treatment group, WT+D-gal treatment group, RINL-KO+NaCl treatment group, and RINL-KO+D-gal treatment group were observed for their individual volume and photographed for record. They were then killed, and their important organs were taken and weighed. The organ weight ratio of each group was analyzed and compared. The results are shown in Figure 8 , Figure 8 A is the weight ratio of each organ in male mice, Figure 8 B is the weight ratio of each organ in female mice. Figure 8 It can be seen that under the induction of rapid aging drugs, the livers of mice in the WT+D-gal treatment group showed abnormal enlargement, while RINL-KO was able to alleviate the abnormal enlargement of the livers of mice induced by D-gal treatment. In addition, brown adipose tissue (BAT) showed significant atrophy and weight loss after D-gal induction, and RINL-KO alleviated this phenomenon induced by D-gal treatment. The abnormal increase in mouse liver weight may indicate the occurrence of a variety of conditions, including obesity, metabolic disorders, inflammation, and fibrosis, while the atrophy and weight loss of brown fat may indicate physiological aging, mitochondrial dysfunction, and metabolic function degradation. The experimental results show that RINL-KO can improve the abnormal changes in the liver and brown fat of D-gal-induced rapid aging female and male mice, which helps to maintain the health of mice.

[0100] The liver tissues of female and male mice in the WT+NaCl treatment group, WT+D-gal treatment group, RINL-KO+NaCl treatment group, and RINL-KO+D-gal treatment group were frozen and sectioned, and the expression of aging markers in the liver of mice in each group was observed using a β-galactosidase (β-gal) staining kit (Biyuntian; C0602). The experimental results are shown in Fig. 9 , Fig. 9 A is the staining result of male mouse liver. Fig. 9 B is the result of female mouse liver staining. The results show that D-gal drug induction significantly increases the expression of aging markers in mouse liver tissue, while RINL-KO can alleviate the degree of aging caused by D-gal induction, indicating that RINL knockout can alleviate the degree of liver aging.

[0101] In summary, the applicant unexpectedly discovered that the expression level of the RINL gene may be related to the degree of individual aging. Experiments have shown that RINL-KO can improve the aging of cells and mice, prolong the lifespan of mice, and improve the exercise and metabolic capacity of aged mice. Specifically, RINL-KO also reduced the expression level of β-galactosidase, a marker of aging, in cells and in the liver of mice. Therefore, the present invention discloses for the first time that RINL can be used as a new target for anti-aging, which is of great significance for screening new drugs and provides a new idea for anti-aging treatment.

[0102] The above is only an embodiment of the present invention, and is not any formal or substantial limitation of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention, and these improvements and supplements should also be regarded as the protection scope of the present invention. Any technician familiar with this profession, without departing from the spirit and scope of the present invention, can make some changes, modifications and equivalent changes made by using the technical content disclosed above, which are equivalent embodiments of the present invention; at the same time, any changes, modifications and evolutions of any equivalent changes made to the above embodiments based on the essential technology of the present invention are still within the scope of the technical solution of the present invention.

[0103] Table 2 Sequence information

[0104]

[0105]

Claims

1. Use of the RINL gene or its encoded protein, wherein the RINL gene or its encoded protein: (1) is used as a marker for diagnosing, detecting or prognosing aging; (2) is used to prepare a reagent or kit for diagnosing or detecting the aging state; or (3) is used to prepare a drug for delaying aging.

2. Use of RINL antagonists in the preparation of drugs for preventing and / or alleviating aging.

3. The use according to claim 2, in, The RINL antagonist specifically targets the nucleotide sequence shown in SEQ ID NO.1 or specifically binds to the amino acid sequence shown in SEQ ID NO.2, and has any of the following functions: (1) Inhibit RINL gene expression; (2) Deletion or silencing of the RINL gene; (3) knockout of the RINL gene; (4) Antagonize RINL protein.

4. The use according to claim 2 or 3, in, The RINL antagonist is selected from shRNA, siRNA, miRNA, dsRNA, stRNA, small molecule compounds, aptamers, antibodies or antigen-binding fragments thereof.

5. The use according to claim 4, in, The antibody or antigen-binding fragment thereof is selected from the group consisting of a whole antibody, a F(ab)-fragment, a F(ab)2-fragment, a single-chain antibody, a chimeric antibody, a bivalent antibody-construct, a synthetic antibody, a bispecific single-chain antibody or a cross-cloned antibody.

6. The use according to any one of claims 2 to 4, in, The medicine comprises an active ingredient, a RINL antagonist, and a pharmaceutically acceptable carrier or excipient.

7. The use according to any one of claims 2 to 5, in, The content of the RINL antagonist in the medicine is 1% to 99%.

8. A method for screening drugs for preventing and / or alleviating aging, comprising the following steps: detecting changes in the expression level of RINL gene in the body before and after administration.

9. A pharmaceutical composition for preventing and / or alleviating aging, comprising a RINL antagonist that inhibits RINL expression, and optionally a pharmaceutically acceptable carrier or excipient.

10. The pharmaceutical composition of claim 9, further comprising one or more additional therapeutic ingredients.

Citation Information

Cited By

  • Anti-aging use of RINL gene and antagonist thereof

    WO2026026919A1

  • Use of RINL gene and antagonist thereof in treatment of obesity

    WO2026026922A1